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Organ transplantation remains the only life-saving
therapy for many patients with organ failure. Despite
the work of the Organ Donation and Transplant Collab-
oratives, and the marked increases in deceased donors
early in the effort, deceased donors only rose by 67
from 2006 and the number of living donors declined
during the same time period. There continues to be
increases in the use of organs from donors after car-
diac death (DCD) and expanded criteria donors (ECD).
This year has seen a major change in the way organs
are offered with increased patient safety measures in
those organ offers made by OPOs using DonorNet
C©
.
Unfortunately, the goals of 75% conversion rates, 3.75
organs transplanted per donor, 10% of all donors from
DCD sources and 20% growth of transplant center vol-
ume have yet to be reached across all donation service
areas (DSAs) and transplant centers; however, there
are DSAs that have not only met, but exceeded, these
goals. Changes in organ preservation techniques took
place this year, partly due to expanding organ accep-
tance criteria and increasing numbers of ECDs and
DCDs. Finally, the national transplant environment has
changed in response to increased regulatory oversight
and new requirements for donation and transplant
provider organizations.
Key words: Deceased donor organs, donation, living
donor transplantation, organ utilization, SRTR/OPTN
Introduction
The organ donation and transplantation community in the
United States continues to undergo dramatic and sus-
tainable change for better performance and quality. Or-
gan transplantation remains the only life-saving therapy
for many patients with organ failure. Despite the work of
the Organ Donation and Transplant Collaboratives, and the
marked increases in deceased donors early in the effort,
deceased donors only rose by a total of 67 from 2006 and
the number of living donors declined during the same time
period. There continues to be increases in the use of or-
gans from donors after cardiac death (DCD) and expanded
criteria donors (ECD). There is a continuation of the Health
and Human Services/Health Resources and Services Ad-
ministration (HHS/HRSA) sponsored collaborative efforts
currently focusing on transplant centers, and their relation-
ships with Organ Procurement Organizations (OPOs), in
order to facilitate growth and efficiency via the Transplant
Growth and Management Collaborative (TGMC). This year
has seen a major change in the way organs are offered and
increased patient safety measures in those organ offers
made by OPOs by the use of DonorNet C©. Unfortunately,
the goals of 75% conversion rates, 3.75 organs trans-
planted per donor, 10% of all donors from DCD sources
and 20% growth of transplant center volume have yet to
be reached across all donation service areas (DSAs) and
transplant centers; however, there are DSAs that have not
only met, but exceeded, these goals. Similarly, there are
transplant centers that have embraced the changes nec-
essary to increase their volume of cases, but not at the
expense of quality in outcomes. Additionally, changes in
organ preservation techniques took place this year, partly
in response to expanding organ acceptance criteria and
increasing numbers of ECDs and DCDs.
Finally, the national transplant environment has changed in
response to the increased regulatory oversight and new
requirements for donation and transplant provider organi-
zations. Centers for Medicare & Medicaid Services (CMS)
regulations for OPOs were published in 2006 and for trans-
plant programs in 2007. These, in addition to voluntary
Joint Commission (TJC) standards and requests by payers
for data, have left some programs beset by the costs of
building and maintaining a necessary infrastructure of per-
sonnel for the perceived divergent and redundant require-
ments for documentation and data submission by separate





















Source: 2008 OPTN/SRTR Annual Report, Table 1.1.
Figure 1: Total number of living and deceased donors of all organs recovered for transplant, 1998–2007.
In the following discussion, we detail the 10-year trends
with data from the SRTR by organ, the current collabo-
rative effort sponsored by the HRSA, and the success of
those efforts and what still needs to be accomplished to
reach the set goals for donor conversion, transplant center
growth, the use of DCD and ECD organs, the transplant
community’s adaptation to DonorNet C©, current trends in
techniques for organ preservation, and increased regula-
tory oversight and transplant providers’ response to these
new changes.
Trends in Deceased Organ Donation
The rate of growth in the yearly number of deceased
donors has shown a marked increase since 2002
(Figure 1) [Table 1.1], which corresponds to the initiation of
the Organ Donation Breakthrough Collaborative (ODBC).
Between 1998 and 2002 deceased donors (defined as at
least one organ recovered) had increased at an average rate
of 99 donors per year. Since 2002, the number of deceased
donors increased by an average of 380 donors per year
[Table 1.1]. This trend appears to have reached a plateau
and the number of donors in 2007 increased by only 67
from 2006. The average increase in deceased donors con-
trasts with a faster increase, followed by a slower increase
and then a decline, in the number of living donors in the
1998 to 2007 time period. The number of deceased donors
has continued to exceed the number of living donors over
the past several years.
Between 2003 and 2004, there was a marked increase
in the number of all three deceased donor types (stan-
dard criteria donors (SCD), ECD and DCD) [Table 2.12].
This increase occurred despite a significant change in
the makeup of the donor population. The percentage of
SCD has been steadily declining, from 78% in 1998 to
about 65% in 2007. This decline can be attributed to in-
creases in the number and percentage of ECDs and DCDs
(Figure 2). Between 2002 and 2004, there was a rapid av-
erage increase of 240 ECDs per year compared with an
average of 160 SCDs and 81 DCD donors; however, be-
tween 2006 and 2007 there was a 2% decrease in the
number of SCDs, a modest 2% increase in the number of
ECDs, and an increase of almost 24% in the DCD category.
Whether this represents a possible saturation of utilization
of the SCD and ECD pools, or a potential effect of DCD
on brain-dead donors (DBD), remains to be seen. By far,
the largest percentage increase in donors in recent years
has been in DCDs, which has significant implications for
overall organ utilization. This increase in DCD explains, in
part, the fewer organs per donor that are recovered and
transplanted overall and the current state of less than 3.75
organs transplanted per donor (OTPD), since the OTPD
was 2.08 for DCD, 1.72 for ECD and 3.63 for SCD in 2007
[Table 2.12].


















Source: 2008 OPTN/SRTR Annual Report, Table 2.12; * includes DCD that meet ECD kidney 
criteria.
Figure 2: Deceased donor
population, by donor type
and year (percentage).
Even though the numbers of consented and transplanted
organs have increased since 2002, other important mark-
ers of organ donation have not dramatically changed much
over the last 10 years (Figure 3). The number of or-
gans recovered per donor (ORPD) and OTPD have de-
clined slightly since 2002. The ORPD dropped from 3.62
in 2002 to 3.5 in 2007, and the OTPD dropped from
3.23 in 2002 to 2.99 in 2007 [Table 2.12]. Among organ


























Source: 2008 OPTN/SRTR Annual Report, Table 2.12.
Figure 3: ORPD, OTPD all or-
gans, 1998–2007.
In 2007, the largest proportion of deceased donors was
ages 50–64 years and comprised almost 26% of the total
donor pool [Table 2.1]. Donors between ages 18 and 34
made up an equivalent proportion of the donor pool. The
number of donors increased the most (36%) in the less
than 1-year-old age group for the 5-year period from 2003
to 2007, while the number of deceased donors ages 12–17
decreased by 6% in the same 5-year period. The percent-
age of donors age 65 years or older has increased slightly,
from 8.9% in 2003 to 9.6% in 2007.
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The percentage of donors dying from anoxia has increased
over the last 6 years, growing from 11% in 1998 to 18% in
2007 [Table 2.1]. This has been accompanied by a similar
decline in the percentage of deaths due to head trauma,
dropping from 43% in 1998 to 37% in 2007. The distri-
bution of causes of death in the other categories has re-
mained relatively stable since 1998.
The growth in multicultural organ donation reflects a com-
bined effect of increases in US multicultural populations
and efforts to increase donation rates among a variety of
ethnic groups. Specifically, while African Americans made
up only 11.5% of donors in 1998, by 2007 15.6% of the
total US organ donors were African American. Similarly,
Hispanics were 9.9% of organ donors in 1998, but in 2007
Hispanics made up 14.1% of the donor population. Thus,
these two groups have increased in both raw numbers and
proportion of donors. The contribution of Asians to the pro-
portion of organ donors has hovered in the 2.0–2.6% range
over the last decade and has not significantly changed.
Recent increases in multicultural donation are substantial
and meaningful, but they continue to lag behind the actual
rates of transplantation and waiting list registrations for
the same ethnic groups. In 2007, while African Americans
represented 15.6% of donors, the group made up 19.4%
of transplant recipients and a dramatic 28.5% of waiting
list patients. Hispanics were 14.1% of donors, 13.0% of
recipients and 16.5% of the waiting list population; Asians
were 2.4% of donors, 4.6% of recipients and 6.4% of
waiting list patients. The gap between donation rates and
transplant rates remains, in part, because the percentage
of recipients is also increasing for all three groups, with
African Americans increasing from 17.3% of recipients in
1998 to 19.4% in 2007, Hispanics from 10.1% to 13.0%,
and Asians from 3.7% to 4.6% [Tables 1.4, 1.10, 2.1].
Deceased kidney donation and utilization
In 2007 there were 15 793 potentially recoverable kidneys
for which consent for donation was obtained. Of these,
1409 (9%) were not recovered, 2389 (15%) were recov-
ered but discarded, 11 752 (74%) were transplanted, and
243 (1.5%) were recovered for research or the disposition
was unknown [Tables 3.1, 3.3]. The distribution of organs
in these categories has been consistent over the 10-year
period from 1998 to 2007. There was a modest average
increase of 178 consented kidneys each year from 1998
to 2002 that accelerated to 1047 between 2003 and 2006;
however, between 2006 and 2007, this number only in-
creased by 161 kidneys. The percentage of kidneys that
were not recovered has gradually increased from 6.6% in
1998 to 8.9% in 2007. The kidney nonrecovery figure is
much lower than the overall average nonrecovery rate of
50%. Despite the increase in nonrecovery rates, the in-
crease in the number of kidney donors has translated into
an increase of 2949 recovered kidneys in 2007 (26%) com-
pared with 2003. The percentage of recovered kidneys that
are discarded has increased gradually from 10% in 1998
to 17% in 2007. The increase was most rapid in 1998 to
2000, declining slightly until 2002, and steadily increasing
each year since then. Despite the increase in discard rate,
the large increase in recovered kidneys since 2002 has
resulted in a large increase in the number of kidneys trans-
planted during this time, from 9694 in 2002 to 11 752 in
2007, an increase of 21.2% compared with an increase
of only 4.4% between 1998 and 2002. The percentage of
consented kidneys that were transplanted in 2007 (74%)
was high relative to the overall average of 43% for all or-
gans. Of kidneys consented, the percentage transplanted
has declined since 1998 (from 82%), but the percentage of
all organs consented that were transplanted has declined
as well (down from 49% in 1998). Again, the increasing
discard rate most likely reflects the increased aggressive-
ness of most OPOs in approaching donor types that would
not have been considered in the past. This trend is con-
firmed in the increasing rates of organs transplanted from
DCDs and ECDs.
Of the 2949 additional kidneys recovered in the 5-year pe-
riod since 2003, 1128 were SCD kidneys, 951 ECD and
870 DCD. The combined ECD and DCD contributions rep-
resent almost 62% of the increase during that time. In
2007, there was only a minimal increase (less than 1%) in
the number of kidneys recovered. There was a small in-
crease in the number of ECD and DCD kidneys recovered,
but 238 fewer SCD kidneys were recovered in 2007 than in
2006. Together, ECD and DCD kidneys now represent 33%
of all kidneys recovered. There has been a shift in the dis-
tribution of recovered kidneys from SCD to ECD and DCD,
which has an impact on utilization, since DCD and ECD
kidneys have higher rates of discard. In 2007, 299 fewer
SCD kidneys were transplanted (compared to 2006); there
was an increase of 163 DCD non-ECD transplants. There
was a small decrease in the number of transplanted ECD
kidneys in 2007 compared to 2006 [Table 2.13].
Deceased liver donation and utilization
Of the 7941 potentially recoverable (consented) livers in
2007, 6229 (78%) were transplanted, 510 (6%) were dis-
carded, 912 (11.5%) were not recovered at the time of
donor surgery, and 290 (4%) were recovered for research,
used for hepatocytes, or the disposition was not reported
[Tables 3.7, 3.9]. The number of consents increased by
less than 1% and the number of transplants decreased by
about 2% in 2007 compared to 2006. The trend in liver
consent was also similar to the overall average, show-
ing an increase of 1,618 (26%) between 2003 and 2007
after an increase of only 401 livers (7%) between 1998
and 2002. Contrary to the trend among all organs, the
nonrecovery rate among livers has declined slightly from
12.6% in 1998 to 11.5% in 2007, a figure much lower than
the average nonrecovery rate among all consented organs
of 50%. The percentage of consented livers that are dis-
carded remained relatively low between 1998 and 2006,
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averaging 4.6%. However, 6.4% of organs were discarded
in 2007. While the number of livers transplanted increased
by an average of 337 per year between 2003 and 2006, a
19% increase, in 2007 132 fewer livers were transplanted
than in 2006. The 78.4% transplant rate among consented
livers in 2007 was much higher than the overall average of
43% for all organs. The number of DCD livers recovered
increased by about 9%, from 407 in 2006 to 444 in 2007,
and now represents 6.4% of all recovered livers and 25%
of all DCD organs [Table 2.15].
Deceased pancreas donation and utilization
Although the number of potential donor pancreata has in-
creased by an average of 482 per year between 2003 and
2007, most of these consented organs have not been re-
covered; the number of pancreata recovered increased by
only 157 between 2003 and 2007 compared with an in-
crease of 1928 consented pancreata during that period
[Tables 3.4, 3.6]. The nonrecovery rate among pancre-
ata is at an all time high of about 72%. The discard rate
among recovered pancreata has also increased gradually
from 10.8% in 1998 to 19.8% in 2007. These trends have
resulted in the number of transplanted pancreata remain-
ing relatively unchanged since 2003. In 2007 there were
6786 pancreata consented, with 382 (5.6%) discarded,
4859 (71.6%) not recovered, 1342 (19.8%) transplanted,
and 203 (3.0%) with another disposition (recovered for re-
search, recovered for islets, or unknown). The 20% trans-
plant rate is lower than the average of 43% for all organs.
The number of recovered DCD pancreata decreased to 64
in 2007 from around 72 to 74 in 2005 and 2006. The 64
DCD pancreata recovered in 2007 represent 3.3% of the
total recovered [Table 2.14].
Deceased heart donation and utilization
After a period of slow increases since 1998, the num-
ber of potentially recoverable (consented) hearts rapidly in-
creased by 1421 organs (30%) between 2003 and 2007 at
an average rate of 355 organs per year [Tables 3.13, 3.15].
In 2007, 6138 hearts were consented, 2239 (36%) were
transplanted, 13 (0.2%) were discarded, 3849 (63%) were
not recovered, and the remaining 37 (0.6%) were recov-
ered for research, heart valves, or the disposition was un-
known. After gradually declining from 2392 hearts in 1998,
the number of heart transplants has been slowly increas-
ing since 2004 and stood at 2239 in 2007. The increase
in available hearts has not translated into an increase in
transplants, due to a growing nonrecovery rate that was
62.7% in 2007. The discard rate for recovered hearts has
remained very low since 1998, at 0.6% or less.
Deceased intestine donation and utilization
In 2007, 6341 intestines were consented, 197 (3.1%) of
these were transplanted, 7 (0.1%) were discarded, 1 (0%)
was recovered for research, and 6136 (97%) were not re-
covered [Tables 3.10, 3.12]. While the number of available
intestines has increased dramatically since 2003 (by 1981,
a 45% increase), most of these were not recovered, as
intestines have the lowest recovery rate of any organ (be-
tween 2.2% and 3.5% over the last 10 years). However,
because of the historically low discard rate among recov-
ered intestines (3.4% in 2007), the increase in recoveries
has led to an increase in the number of organs transplanted
from 112 in 2003 to 197 in 2007.
Deceased lung donation and utilization
In 2007, 13 317 lungs were potentially recoverable, 2471
(18.6%) were transplanted, 70 (0.5%) discarded, 34 (0.3%)
were recovered for research or disposition was unknown,
and 10 742 (80.7%) were not recovered [Tables 3.16, 3.18].
With a marked increase in the number of lungs available
since 2003 (3027 lungs, a 29% increase) and a very low
discard rate among recovered organs (about 2.5% since
2000), the percentage and number of lungs transplanted
is continuing to increase. There were 46% more lung trans-
plants in 2007 (2471) compared to 2003 (1692). The con-
tribution of DCD lungs remains low; only 19 of the 2575
lungs recovered in 2007 were DCD [Table 2.18].
Trends in Living Donation
The number of living donors has declined for the third con-
secutive year, after increasing by 53% from 1998 to 2004
[Table 1.1]. There were 6308 living donors in 2007, down
424 (6.3%) from 2006 [Table 1.1]. Since 1998 the vast ma-
jority of living organs donated have been kidneys (almost
96% in 2007), followed distantly by livers (4% in 2007) and
last (at less than 1%) by other organs. The small decrease
in living donors in the past 2 years may represent a satura-
tion point in the supply of living donors, or may be related
to the increase in transplants from deceased donors.
Living kidney donation
After growing from 4422 donors in 1998 to 6647 donors
in 2004, living kidney donation leveled off and has since
declined slightly to 6036 donors in 2007 [Table 2.9]. The
trend toward an older age distribution of living donors con-
tinued in 2007. The percentage of donors ages 50–64 years
continued its gradual 10-year increase to 23.5% in 2007,
up almost 2% from 2006. Between 2006 and 2007 the
percentage of donors in the 18–34 age group declined by
about 0.8%, while donors ages 35–49 years declined by
1.4% to 44.2% [Table 2.9]. The very young and very old
categories continue to represent only a small fraction of
donors. There were no donors in the 12–17 age group in
2007, and only 1.4% (an increase from 2006) of all donors
were older than 65 years.
The number of full sibling and parent living donors is at a
decade-long low. Although there are still more living kid-
ney donors in the ‘full sibling’ category than any other,
they declined from 37% of all donors in 1998 to 24% in
2007 [Table 2.9]. The percentage of parent living donors
has dropped from 18% in 1998 to 10.8% in 2007. The
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percentage of ‘spouse unrelated’ and ‘other relative’
donors in 2006 and 2007 remained stable at 12% and 8%,
respectively. The largest increase has come in the ‘other
unrelated’ category, which has risen from 362 donors in
1998 to 1416 donors in 2007, and now represents about
24% of all donors, the second largest category. This in-
crease in unrelated donors probably reflects a broader ac-
ceptance of living donation and the increasing recognition
of potential donors outside the recipient’s immediate fam-
ily (friends, coworkers, etc.), although live altruistic donors
may also represent a small portion of this increase. Off-
spring living donors represented the third largest category
at 16.2% in 2007.
The composition of living kidney donation by race and sex
has not changed significantly over the last 10 years. The
majority of donors have been white, representing about
70% of the total number of living donors. In previous years
African American and Hispanic/Latino donors each made
up similar proportions of the living donor pool, but in 2007
13.1% of the living donors were Hispanic compared to
12.1% African Americans. Asian donation has ranged be-
tween 3% and 4%, while donors in the ‘Other/Multiracial’
and ‘Unknown’ categories have never represented more
than about 1% of all donors. Female donors have con-
sistently maintained a 14–18% higher representation
than males among living donors over the past decade
[Table 2.9].
Living pancreas donation
There were no living pancreas donations in 2007, continu-
ing the declining trend from 2000, when there were seven
living donor pancreas donations [Table 1.1].
Living liver donation
The number of living liver donors decreased slightly to 266
donors in 2007, down from 323 in 2005, where it had
remained steady for 3 years after declining from a high of
522 donors in 2001 [Table 2.10]. In 1998, 63% of living liver
donors were parents. By 2007, due to the increase in per-
formance of adult live donor liver transplantation, this had
dropped to 23%, almost the same proportion as offspring
donors. Offspring now represent the leading category of
living liver donors, 23.7% in 2007. ‘Other relative’ donors
made up 12% of all living liver donors in 2007, and spouse
donors made up 4.5%. In 1998, 59% of living liver donors
were ages 18–34 years, 34% were in the 35–49 age group,
and less than 8% were ages 50–64 years. Ten years later,
in 2007, the percentage of donors in the 18 to 34-year-old
group dropped to 42.5%, the percentage who were 35–49
years increased to 41.7%, and the percentage in the 50–64
bracket gradually increased to 14.7% [Table 2.10]. These
age trends indicate a steady increase in the average age of
living liver donors over the last 10 years. The demographics
of race and sex have remained relatively stable in the living
liver donor population in the same period. The percentage
of Asian donors in 2007 increased 1% since 1999 and the
percentage of Hispanic liver donors increased in 2007 after
having decreased since 2002 [Table 2.10]. A predominance
of female donors exists in living related liver donation, as
just a little over half (50.8%) of living liver donors were
female in 2007.
Living lung donation
For the third year in a row, the number of living lung donors
has been extremely small. There were only six living lung
donors in 2007, after dropping from 25 to 29 living lung
donors per year between 2002 and 2004 [Table 2.11].
Transplant Growth and Management
Collaborative
As a continuation of the Organ Donation and Transplant
Collaboratives initiated in 2003, the Transplant Growth and
Management Collaborative (TGMC) was launched in Octo-
ber 2007 to focus on the transplant programs. The goal of
this new collaborative effort is to provide transplant pro-
grams the tools to share practices from high-performing
transplant programs and to develop the necessary capac-
ity in all programs to increase transplant volume by 20%
by 2012. Through a systematic review of programs that al-
ready experienced this level of growth, and maintained or
exceeded graft- and patient-survival expectations, HRSA
identified six strategies that appear fundamental to suc-
cessful growth and were common among these centers
(Table 1). Together with OPO partners, more than 60 trans-
plant hospitals have established growth goals for at least
one major organ (heart, liver, pancreas and/or kidney) and
have been learning, testing and reporting these changes at
national meetings. Participating transplant programs have
adopted internal structure and process changes to their
hospital or health system in cooperation with their OPO to
grow their programs. Some of the changes most frequently
tested by TGMC teams involve recommitting/restructuring
hospital administrative and clinical leadership and gover-
nance structures of the transplant program; using proven
quality improvement methods to identify and test solutions
to problems; creating/revising quality improvement dash-
boards; strengthening patient referral outreach programs;
streamlining candidate pretransplant evaluation processes;
revising job descriptions to better match qualifications to
responsibilities; and utilizing the Report of Organ Offer
Turndown (ROOT) to systematically review the reasons for
organ offer turndown decisions (and the ultimate disposi-
tion of declined organs) in collaboration with the OPO to
Table 1: Best practices
1 Institutional vision and commitment
2 Dedicated team
3 Aggressive clinical style
4 Patient and family-centered care
5 Financial intelligence
6 Aggressive management of performance outcomes
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Figure 4: TGMC actual OTPD
by OPTN region.
educate clinicians and improve local organ acceptance. The
ROOT was developed by UNOS using OPTN data and is
available to every OPO and transplant program online.
An early performance metric of the TGMC participating
teams is the time from patient referral to a center to the list-
ing of the patient (1). Substantial decreases in the median
number of days from the referral of a transplant candidate
to activation on the waiting list has been demonstrated by
monthly report cards by participating centers on the na-
tional results sharing site. This process improvement has
been accomplished by a number of strategies, such as en-
gaging patients in commitments to complete evaluations
in specified time frames; restructuring job descriptions for
nursing and nonnursing staff; and including referral to wait-
ing list time targets in the transplant program’s quality im-
provement dashboard.
Despite all of these process improvements, increasing
transplant volume remains solely dependent on increas-
ing organ availability. Since 2003, organ availability has in-
creased in 47 of 58 DSAs in the United States and the
magnitude of growth ranges from 1% to 100%. The na-
tional US conversion rate continues climbing toward the
75% goal. It was at 69% for 2007, up from 50% at the in-
ception of the ODBC in 2003. The number of OTPD has not
increased. Monthly 2007 OTPD rates range from 2.96 to
3.15 (includes all donors) and remains relatively unchanged
from 2006 (Figure 4). There has been a steady increase
in the number of monthly transplants made possible by
donors after cardiac death (Figure 5).
Increasing the nation’s conversion rate to 75% remains an
important priority. At the conclusion of 2007, 19 of 58 DSAs
achieved this performance benchmark, and an additional 13
DSAs exceeded the 70% level. Opportunities for improve-
ment still exist in all DSAs and likely hinge on the ability to
convert more eligible donors among ethnic minorities. By
reviewing the conversion rates by OPTN region the impact
of donor demographics can be demonstrated, as only 3 of
the 11 regions meet or exceed the 75% conversion rate
(Figure 6). Throughout 2007, the OPTN OPO Committee
laid the foundation for demographic data to be collected
on all eligible deaths (meeting the OPTN definition) and
imminent deaths (those likely to meet the definition within
the next 24–48 hours) that identify DSAs from which best
practices in working with minority donor families and pedi-
atric eligible donors can be learned. Using the Collaborative
infrastructure, these practices can be shared, learned and
adapted by other DSAs with the goal of bringing each DSA
to the 75% conversion rate benchmark.
While progress toward bringing hospitals and entire DSAs
to the 75% conversion rate level has been encouraging,
similar success in increasing the number of organs trans-
planted per donor to a national average of 3.75 has not
been evident. Since the start of the Transplant Collabora-
tives, the national rate of organs transplanted per donor
has remained relatively unchanged. Unlike the conversion
rate goal that has been measured and tracked at the hos-
pital, DSA, and national levels, the OTPD goal has been
perceived as a benchmark that could only be improved
by implementing changes at the DSA level. One impor-
tant DSA change that has been successfully achieved in a
few DSAs is the integration of critical care specialists into
the donor management process, such as the Baltimore
(MDPC) DSA’s real-time involvement of critical care spe-
cialists in donor management and the St. Louis (MOMA)
DSA’s goal-directed donor management process that is
overseen by an advisory committee of critical care practi-
tioners. Both DSAs are achieving increases in OTPD and
organ availability that are directly related to partnerships



























































































































































Cardiac death donors standardized to 30-day month
Source: OPTN database as of 3/2008
Month/Year
Figure 5: HRSA cumulative collaborative data trends in donation after cardiac death.
with hospital-based critical care experts. While DSA-level
changes are necessary to generate nationwide improve-
ments, developing hospital-level changes may prove instru-
mental in producing DSA-wide change.
Achieving the three collaborative goals (75% conversion
rate, 3.75 OTPD, and 10% DCD) nationwide is most likely
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Note: Range of conversion gap is 3.3 percentage points above the goal to 14.7 percentage 
points below the goal.
OPTN Region
Figure 6: TGMC con-
version gaps by OPTN
region, May 2007–April
2008.
tively implement leading donation practices. An essential
aspect of any collaborative is disseminating the best prac-
tices developed by a few high performers to all participat-
ing hospitals, a process known as a ‘spread strategy’. The
Organ Donation Collaborative initiated its spread strategy
in 2005, and since 2007 has focused on raising the per-
formance of the 400 US hospitals with 8 or more eligible
deaths in a 12-month period to goal levels. In 2007, nearly
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30% of the spread target hospitals met the 75% conver-
sion rate goal, 50% met the DCD goal, but only 14% of
target hospitals met the 3.75 OTPD goal. As with all as-
pects of organ donation performance, the effectiveness
among the 11 OPTN regions in achieving the goals of the
spread strategy varies (Figure 4).
In mid-2006, the Collaborative and the OPTN embarked
on a joint effort utilizing OPTN regional education forums
as mini-collaboratives to educate and cultivate OPO, trans-
plant program, and local donor hospital action to achieve
the national goals. Since that time, individual regional
teams have reviewed regional performance data and imple-
mented half to whole day education sessions in conjunc-
tion with the regularly scheduled OPTN Regional Meet-
ings. The agenda is designed to address topics that will
help the regional DSAs recognize and close performance
gaps. Meeting organizers and leaders consist of regional
OPO representatives, key transplant surgeons/physicians,
and critical care physicians. Based on performance needs,
regional participants have already embarked on initiatives
to better understand the reasons for organ discard; devel-
oping and evaluating the impact of meeting donor man-
agement goals on OTPD; improving pediatric OTPD; and
incorporating DCD into end-of-life care programs. Travel
to national collaborative meetings for all donor hospital,
OPO, and transplant program staff is not practical and can
be cost prohibitive. Providing the option of regional mini-
collaborative meetings permits many more professionals
to learn about, and commit to achieving, the goals of the
Breakthrough Collaborative.
DonorNet
One of the most significant changes that has occurred
during this time period has been the introduction, and
widespread adoption, of a nationwide, electronic organ of-
fer system. In April of 2007, the organ allocation system
in the United States underwent a dramatic change with
the OPTN-mandated conversion to what is known as the
DonorNet C© system. Creating an electronic system to of-
fer organs by the OPO and field those same offers by the
transplant center was mandated by the contract awarded
to UNOS to administer the OPTN by the Division of Trans-
plantation within the Department of Health and Human
Services. The goals of the Federal regulators in requiring
this change were multiple: (1) reduce and ultimately elimi-
nate any skipping of the patient list in the organ offer pro-
cess, such that members of the public and patients on the
waiting list alike can be assured that offers were made in
the order that patients are ranked on the waiting list, (2)
authenticate decisions made by the transplant center per-
sonnel in a way that these decisions and the appropriate
refusal codes could be made in real time and could subse-
quently be audited, to adjudicate any conflicting account
between OPO and transplant centers, and (3) speed the
process of organ offers to maximize the number of patients
who could potentially benefit from an available organ (2).
The OPTN Operations Committee, charged with the re-
sponsibility of developing DonorNet C© in conjunction with
UNOS staff, seized the opportunity to try to design a sys-
tem that maximized patient safety and efficacy of commu-
nication that a web-based electronic system could bring.
The creation of DonorNet C© forced OPOs to move away
from a paper-based system and to one in which donor
information was entered into an electronic database that
would then be uploaded directly into DonorNet C©. The real-
ity of DonorNet C© as an operational entity has facilitated the
development of a sister entity, the TTSN (Transplant and
Tissue Sentinel Network) spearheaded by the Centers for
Disease Control. The goal of the TTSN is to trace forward
any tissue donor, and to trace backward any organ donor,
for communicable diseases (infectious or malignant) (3).
Once one or more preliminary acceptances for organs of-
fered have been entered, the OPO may then contact the
transplant center representative by phone to further ex-
plore the organ offer, answer any specific donor manage-
ment questions, accept requests from the center(s) for
additional information, and ultimately to confirm the accep-
tance of each organ by a center. When organs have been
accepted, the offering OPO, the receiving OPO (if differ-
ent), and the transplant center(s) then work to coordinate
the recovery, transportation, necessary cross-matching,
and eventual transplantation of the organs.
The DonorNet C© system has numerous goals and poten-
tial benefits, including accurate documentation of all offers
made and received, documentation of review of critical
donor information with each offer by the accepting cen-
ter (standard screen for ABO typing, results of serological
testing, pressor or inotropic medication use), if it was ac-
cepted or declined, more accurate refusal codes and other
valuable information on allocation that can be studied to
hopefully improve organ utilization. A primary goal of the
system was to increase the number of offers made and
the efficiency of making such offers with the desired ul-
timate outcome of increasing the number of organs suc-
cessfully transplanted. It was also developed to improve
patient safety on both the donor and recipient side (4). At
least to this point in time, data would not tend to support
the primary goal of increasing transplants per donor, as
the number of organs placed per donor has essentially not
changed in the early DonorNet C© period from the period
immediately pre-DonorNet C© (4,5).
Despite the relative lack of impact on organs transplanted
per donor, the success or failure of the DonorNet C© sys-
tem is, as of yet, to be determined. It has clearly made
the allocation process uniform for data presentation to
the accepting center, and ensured that issues of patient
safety are addressed (i.e. ABO incompatibility). First, the
point must be made that the data are very preliminary and
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drawing any significant conclusion currently assumes no
change in the demographic of the donor population, de-
spite the relative lack of impact on organs transplanted per
donor (the reason for this may be multifactorial and not per
se the result of DonorNet use). A more thorough analysis
of data, comparing placement rates in subsets of donor de-
mographics and drawn from data collected over a longer
period of time, will be necessary before DonorNet can be
evaluated thoroughly.
A second key point is that the DonorNet C© system is clearly
a work in progress (5), with key utilities, data points and
guidelines for use still in a relatively fluid development
stage. Included examples of this fluidity are: changes in
the patient and/or center-specific screening criteria that a
center may enter, changes in how OPOs are allowed to
handle zero mismatch kidney offers (through the UNOS
Organ Center versus directly between OPO and transplant
center), and the number of offers that an OPO can instruct
the DonorNet C© system to make simultaneously. These are
but a few of the examples of adjustments to the system
that theoretically have an impact on the overall effective-
ness of DonorNet C© and, therefore, a direct impact on any
data that may be used for evaluation.
Finally, it must be noted that both OPOs and transplant
centers are still learning how to efficiently use the sys-
tem and are adapting themselves to the new world of
electronic notifications. This evolution will likely take con-
siderably more time until a standard of practice, or best
practices, for utilization of DonorNet C© is well established.
For OPOs, some of the issues currently being evaluated
are:
• Beyond the information required to make an offer,
how much additional information is it optimal to en-
ter before initiating placement and how often should
that data be updated during the allocation process? In
some DSAs, the OPO is entering limited information,
sending out many offers, and then going into more
details in the phone conversations that result from
preliminary acceptance. In other DSAs, the OPO is
entering significant amounts of lab, hemodynamic,
and other data including reports or actual radiographs
of cardiac angiograms, echocardiograms, and bron-
choscopes before any attempt of organ placement is
made.
• The number of offers to make initially and how far
to go down the list before stopping are both unclear.
Some single-center OPOs have used the DonorNet C©
system to assure not only patient back-up, but cen-
ter back-up for each organ, making large numbers
of offers until they have several centers lined up for
back-up (6).
• When and if to cease placement through the list and
move to placement with aggressive centers (expe-
dited placement) remains a topic of much discussion.
In the pre-DonorNet C© days, it was thought that Donor-
Net C©, by virtue of expected speed and efficiency via
electronic offers, would eliminate the need for expe-
dited placement; however, with over a year of us-
ing DonorNet C©, it is apparent that at times there is
still a role for an expedited placement model in many
OPOs’ practice to prevent organ discard (7).
For transplant centers, some of the issues include:
• How to set the organ screens to minimize the amount
of unwanted organ notifications and to maximize the
amount of useable organ notifications (4).
• When and how to choose a DonorNet C© intermediary
that could potentially lower the organ donor screens
without adding to fatigue of the physicians and sur-
geons with offers that may not be pristine. With the
inception of DonorNet C©, the number of calls has
increased significantly to transplant programs (4,5).
There is no funding from the payers or the OPTN
to support such intermediaries, and in some DSAs,
state laws and issues of malpractice coverage pre-
vent some OPOs from acting as that intermediary
(6).
• How to cope with the required adaptation to
new technologies, including personal computers and
PDAs. This is not an easy transition for many physi-
cians and surgeons who have been in practice for
decades.
• Regarding local donors, can the system be updated
so that donors can be accepted if allocated as local,
versus a separate notification for each organ to the
same thoracic and abdominal program? One center
could potentially receive seven notifications (heart,
lung, heart-lung, liver, kidney, kidney-pancreas, and
pancreas alone) as the system is currently configured,
leading to fatigue, lack of efficiency in the placement
of organs and potential delay in recovery.
• For large centers, with large kidney and pancreas lists
that are still based on waiting time to be transplanted,
DonorNet C© efficiency mandates that of the patients
listed, all should be eligible for transplantation at the
time of the organ offer (to streamline the offer process
and avoid delays in offering the organ to a patient who
is not ready to be transplanted). This requires closer
monitoring of these patients by pretransplant per-
sonnel, including physicians, social workers, financial
coordinators and histocompatibility personnel along
with the availability of work-up data and routine health
maintenance records by those making organ accep-
tance decisions. These requirements mandate more
center clinical infrastructure in order to see patients
more frequently and a tracking system or database
that is available on- and off-site, to facilitate organ
acceptance.
While this is only a superficial list of the issues and
questions that have been identified in the early days of
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DonorNet C©, it illustrates the amount that the transplant
community does not yet know, understand, or agree upon
regarding this exciting new tool. It is clear that DonorNet C©
and its system of electronic notification is much faster than
making individual phone calls for offers and is potentially a
beneficial tool in placing organs while maximizing recipient
safety. However, careful study of the data that DonorNet C©
itself is allowing the OPTN to collect is necessary and,
where needed, carefully planned adjustment of the sys-
tem is also necessary to assure the success of DonorNet C©
in the long-term. DonorNet C© as a communication tool has
truly revolutionized information transfer from the OPO to
the transplant center and is instrumental in ‘pushing’ avail-
able organs to the end-user.
Organ Preservation
In response to expanding organ acceptance criteria and in-
creasing numbers of ECDs and DCDs, changes in organ
preservation techniques took place this year. The percent-
age of deceased donor kidneys that are currently placed
on pulsatile perfusion, or pumped, is increasing, with DCD
kidneys pumped at the highest rates, followed by ECD
kidneys and SCD kidneys (8). Local practices vary consid-
erably; in some OPOs all kidneys are routinely pumped,
in others only DCD or ECD kidneys are routinely pumped,
and in others, kidneys are pumped selectively based on
individual OPO criteria (9). Analyses of deceased donor
kidney discard suggest that a kidney that is pumped is less
likely to be discarded (10). While this suggests that OPOs
can decrease discard rates by more frequent pumping,
analyses performed by the OPTN Organ Availability Com-
mittee indicate that OPOs that pump a higher percentage
of kidneys do not have lower discard rates (9). This ap-
parent paradox appears to be best explained by the finding
that discard rates of kidneys that are not pumped are signif-
icantly higher in OPOs that pump more frequently (Table 2).
In addition, kidneys that are pumped in OPOs that pump
less frequently are much more likely to be discarded; how-
ever, OPO practices appear to matter less with respect to
the discard of ECD kidneys, as pumped ECD kidneys are
discarded less frequently regardless of OPO practice. This
suggests that routine pumping of ECD kidneys may impact
utilization (10).
Table 2: Unadjusted percentages of recovered kidneys that were discarded, based on OPO pumping practices
Pumping practice
Pumped 0 Pumped ≤50% Pumped >50%
Type Not pumped Not pumped Pumped Overall Not pumped Pumped Overall
SCD 7.4 7.5 13.9 7.8 20.7 4.9 9.3
ECD 41.2 43.7 30.8 40.2 69.9 23.0 33.6
DCD 22.9 16.6 17.7 17 41.5 17.4 20.5
All 15.3 13.4 21.1 14.2 30.9 8.5 14.8
Among kidneys recovered January 1, 2001–July 31, 2004.
Aside from the potential impact of pumping on utilization,
multiple analyses have demonstrated significant reduc-
tions in the odds of delayed graft function for kidneys that
are pumped (10,11). This reduction in delayed graft func-
tion has implications for recipient length of stay and overall
costs of transplantation. Cost analyses have demonstrated
a beneficial effect of pumping on transplant finances (12).
For these reasons, the OPTN Board of Directors approved
the premise that access to machine preservation should
be available in all DSAs.
Registry analyses do not demonstrate beneficial effects
of machine perfusion on graft survival for any class of de-
ceased donor kidneys (9). However, in the recent European
prospective, randomized, controlled trial of machine perfu-
sion, machine perfusion significantly reduced the risk of
both delayed graft function (DGF) and graft failure (11). In
addition, among those kidneys with DGF, graft survival at
6 months was 87% in the pumped kidneys versus 76% in
those not pumped. These data indicate a potential graft sur-
vival benefit to allografts that are implanted after pulsatile
perfusion.
Another trend in organ preservation this year was an
increasing use of an alternative preservation solution,
histidine-tryptophan-ketoglutarate (HTK). The purported
advantages of HTK in abdominal perfusion, over the more
commonly used University of Wisconsin (UW) solution,
are reduced costs and a potential for reduction in biliary
complications in liver transplantation due to lower viscos-
ity. While relatively limited, published literature exists re-
garding the efficacy of HTK compared to UW, and several
single-center analyses indicate equivalent rates of kidney
graft survival and a reduction in delayed graft function asso-
ciated with HTK, along with a significant cost savings (12–
14). Multiple single-center studies have also demonstrated
equivalent outcomes in pancreas transplantation compar-
ing HTK with UW (15–18). Similar results have been seen in
liver transplantation, although the theoretical benefit on bil-
iary complications has not been confirmed (19,20). While
SRTR analyses performed for the OPTN have also not
demonstrated an increased risk of graft failure associated
with HTK in kidney or pancreas transplantation (21,22), re-
cent reports using OPTN data suggest significantly worse
liver and pancreas graft survival rates associated with HTK
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Table 3: Changes in DCD and DBD utilization within DSAs, 2006 to 2007
Average percent change from 2006 to 2007
Change Number Change Change Change in Change in
in DCD of OPOS in SCD in ECD DCD & ECD∗ Non-DCD
Decrease 17 5.17 −0.30 −46.01 2.77
0 DCD both years 1 26.42 112.00 . 53.85
0–50% increase 18 −1.69 7.42 59.42 −1.54
50–100% increase 11 −5.28 3.73 −10.00 −3.50
>100% increase 8 −1.94 23.46 275.00 −1.14
0 DCD in 2006, >0 DCD in 2007 3 2.23 90.50 . 8.36
Total 58 0.29 12.77 28.45 0.87
∗A total of 233 donors were donors after cardiac death and also meet expanded criteria. These donors are not included in the DCD only
or ECD only categories.
preservation. These reports warrant continued evaluation
of outcomes in light of the increasing use of HTK in organ
preservation (23,24).
Donation After Cardiac Death
Due in part to the goals set by HRSA for DCD develop-
ment, the percentage of donors that come from DCD con-
tinues to increase. There has been a total increase in the
percentage of donors that are categorized as DCD, from
8% in 2006 to 9.8% in 2007, and the number and per-
centages of DCD liver and kidney transplants continue to
increase substantially [Tables 2.1, 2.2, 2.4]. Available data
continue to support the notion that kidney transplant graft
survival from DCD donors is equivalent to those of brain
dead donors under most circumstances (25,26). A notable
exception is older or ‘ECD–type’ kidney donors where in-
creased graft failure attributable to the DCD status has
been noted (26,27). The increased risk of graft failure as-
sociated with DCD liver transplants continues to limit the
use of these organs (28). In addition, the significant risk
of biliary complications that dramatically impairs recipient
quality of life, if not graft survival, has become increasingly
recognized (29,30). These concerns are reflected in the de-
creasing percentage of DCD donors in which a liver is used
for transplant.
With the rapid increase in DCD relative to donation after
brain death (DBD) in the past several years lies the possi-
bility that some DCDs are occurring from donors that may
have previously progressed to brain death. Since ORPD
and OTPD are lower for DCD, this has potential implica-
tions for overall organ utilization. A 2005 SRTR analysis
demonstrated a positive relationship between the number
of DCDs and DBDs in a DSA. Although analyses of donor
types by DSA in 2006 and 2007 do not show a significant
correlation between changes in DCD and DBD within DSAs
(r = −.15, p = 0.25), there was a negative correlation be-
tween changes in DCD and SCD from 2006 to 2007 (r =
−.0.29, p < 0.05). Among the 17 DSAs that saw a decline
in DCD from 2006 to 2007, the average increase in DBD
and SCD was 2% and 5%, respectively. However, in those
37 DSAs where DCD increased in 2007, on average the
numbers of both DBD and SCD declined (Table 3).
There are many influences on the changes in donors over
time. In addition, it is well established (although anecdotal)
that a certain percentage of donations would not proceed
were it not for the DCD option, either because of timing
conditions placed on the consent, or due to lack of progres-
sion to brain death. Nevertheless, because of the poten-
tially significant impact on utilization, the apparent inverse
relationship between changes in DCD and DBD warrants
further monitoring.
The potential progression of patients who would poten-
tially qualify for DCD to brain death may also be impacted
by the success of donor registries. As the number of poten-
tial donors who have participated in a registry increases,
this may permit a greater propensity to wait for progres-
sion to brain death among donors initially considered for
DCD.
CMS and Joint Commission
Oversight/Regulations
Finally, one of the most recent significant changes in the
transplant environment in the United States has been
the increased regulatory requirements for donation and
transplant provider organizations. In May 2006, CMS pub-
lished its Final Rule outlining the conditions of participa-
tion (COPs) for OPOs in the United States. This document
establishes new conditions for coverage for OPOs that
include multiple new outcome and process performance
measures based on organ donor potential and other related
factors in each service area of qualified OPOs’. Its stated
goal is ‘to improve OPO performance and increase organ
donation’ (31).
The Final Rule established the following outcome or per-
formance measures. All three must be met (32):
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1. Donation or Conversion Rate—The number of actual
donors as a percentage of the potential donor pool.
Specifically, the OPO is required to have a dona-
tion or conversion rate no more than 1.5 standard
deviations below the national mean.
2. Expected Donation Rate-–The OPO should have an ob-
served donation rate that is not statistically lower
than the expected donation rate for the OPO, as
calculated by the SRTR, for 18 or more months of
the 36 months of data used for recertification.
3. At least two of the following three yield measures are
achieved at no less than one standard deviation be-
low the national mean:
• Number of organs transplanted per SCD
• Number of organs transplanted per ECD
• Number of organs used for research per donor
The above are slightly modified for those OPOs function-
ing exclusively in non-contiguous states or territories in that
number of organs transplanted is replaced by number of
kidneys transplanted under performance measure three.
The data to be used for evaluating OPO performance rel-
ative to expected donation rates are a 36-month period
beginning January 1, 2007.
These performance measures represent a significant de-
parture from the previous population-based measures (i.e.
donors per million population) of the preceding COPs. In
large part, this evolution began with a growing acceptance
within the donation community that not all populations are
demographically equal and therefore comparing/evaluating
performance of 58 diverse OPOs based upon measures
of anything per million population would be inherently
flawed. The OPO community has changed to potential per-
formance metrics (such as conversion rates that measure
actual donors as a percentage of the eligible donor pool)
or donor demographics (SCD vs. ECD). While it is still a bit
early in the process of applying these new standards to
evaluate their validity, the intent was to move toward per-
formance measures driven more by donor potential and
demographics than sheer numbers of people within the
DSA.
Preliminary evaluation of data applicable to the OPO out-
come measures is based upon SRTR data for OPOs from
August 1, 2006 through December 31, 2007. The data in-
clude the individual standard; the high value, low value
and the mean for the standard as determined by analyzing
the 58 OPOs’ data; and the number of OPOs that would
currently fall below the outcome measure as defined by
CMS.
Outcome measure one (donation or conversion rate): 4 of
58 OPOs fell more than 1.5 standard deviations below the
national mean for the initial 17 months of the 4-year re-
certification cycle. At this early date (roughly one-third of
the way through the recertification cycle) it is not possi-
ble to draw any significant conclusions regarding the per-
formance of either individual OPOs, or the industry as a
whole, but as the cycle progresses, and with more in-
depth evaluation of those falling below the measure, it
should be possible to evaluate the scientific merit and im-
pact of this measure as it relates to the CMS recertification
process. What is possible at this time is to compare, in the
broader sense, the mean conversion rate for this limited
timeframe (67.1%) to where the industry was at only 5
short years ago (roughly 50%). National focus on this per-
formance measure has helped OPOs and the industry as a
whole to progress significantly in a relatively short amount
of time, with all but one OPO above what was the average
until recently.
Outcome measure two (observed donation rate versus ex-
pected as calculated by the SRTR) was not evaluated for
this article, as expected data modeling has been revisited
recently and 2007 expected data have not yet been pub-
lished. When available, these data will be published for
each OPO online at www.ustransplant.org and available to
the public.
Of the three possibilities listed for the final outcome mea-
sure (see point three, above), research organs per donor:
three of 58 OPOs fell more than 1 standard deviation from
the mean for the initial 17 months of the 48 month cy-
cle. It is very difficult to interpret these data, however, as
it is unclear if CMS will include in their final analysis all
organs sent to research of any kind, only those organs in-
tended for research prior to recovery, or if there will be
criteria set for research that will preclude certain types
of uses from inclusion. What is clear is that a wide va-
riety of practices exist with regard to use of organs for
research and it is difficult to place any merit on the exist-
ing data because of the lack of common definitions either
in the field or as published by CMS with regard to this
measure.
It is important to qualify two other matters regarding this
discussion. First, for the purposes of this article, there
was no attempt to apply the separate ‘kidneys per SCD
or ECD’ standard for OPOs operating exclusively in non-
contiguous US states or territories, as this article is a pre-
liminary overview of how application of these measures
looks based upon limited data. Illustrating this does not
necessitate the extra level of data analysis at this point;
clearly, this differentiation will be crucial when CMS actu-
ally applies these standards at the end of the designation
cycle. Second, the research information presented here is
not screened or filtered in any way; in other words, all or-
gans deemed as sent to research by the OPO have been
included here regardless of intent at time of recovery and
regardless of any definition of research that might include
or exclude certain organs.
For transplant centers, TJC standards were published
in January of 2007, as well (Table 4). Participation for
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Table 4: TJC standards
Medicare provider agreement and participation in the OPTN
Organ procurement, recovery and receipt
Organizational leadership structure
Selection of patients and living donors, as well as managing care
and respecting patient and donor rights
Coordination of care, including pre- and postsurgical processes
Qualifications of caregivers
Staff competency and training
Information management
Standardized performance measurement and data submission
Performance assessment and improvement
certification was and is voluntary, with centers paying a
fee for a TJC site visit and certification.
While TJC certification program was developed in con-
cert with the CMS standards published in March 2007,
TJC standards assess a program’s compliance with quality
standards (31). The CMS COPs (Table 5) are a direct re-
sponse to public concern and comments regarding explicit
standards of outcomes of transplant services. Prior to the
new COPs, CMS relied on transplant centers to self report
significant changes and major issues that might mandate
a CMS site visit. The current COPs are expected to clarify
and reinforce normal business practices of most transplant
centers, as well as accountability for the services that they
provide as an outcome-based system.
The data submission requirements are similar to those al-
ready in place for compliance with the OPTN requirements
of 95% data submission within 90 days for deceased organ
transplants. Outcome measures are based on the time pe-
riod for patient and graft survival calculated by the SRTR.
Graft and patient survival rates that fall below expectations
will trigger a CMS review and corrective action. Process
requirements address a number of issues in patient and
donor selection and care during the transplant process. Per-
haps, most importantly, the requirements focus on stan-
dardization of the living donor process, informed consent,
separate living donor advocates, and transparent disclo-
sure of what is known about short- and long-term risks of
donation and the possibility of lack of health care cover-
age due to these complications. While the intent of these
regulations is to help assure a standard quality of care for
Medicare recipients, they also increase the resources nec-
essary to operate a transplant program.
Transplant centers answer to many governing and regu-
latory bodies, including the OPTN, state and institutional




regulators, CMS, payers, and potentially TJC. Responding
to various audits, reviews, and requests for information
takes time and personnel. For centers that do not meet
the COP requirements, personnel will need to be hired,
and potentially infrastructure created. For CMS, there will
be expenses for audits and site visits that are likely to be
passed along to the transplant centers. Often, transplant
centers feel the burden of sometimes divergent and re-
dundant requirements from these various entities. A sim-
ilar environment existed in the patient safety arena until
2005, when regulatory harmonization between multiple
regulatory bodies occurred (CMS, TJC, Leapfrog Group, In-
stitute of Health Care Improvement, Agency for Healthcare
Research and Quality) and was submitted to the National
Quality Forum in order to update and streamline health care
providers’ and institutions’ response to maintaining Safe
Practices. This harmonization effort’s intent was to limit
confusion and redundancy amongst care providers while
maintaining compliance with patient safety practices. This
effort has been championed by the Safety leaders and par-
ticipating organizations, and continues to date (33). Such
an effort may help rationalize the various requirements for
transplantation.
Summary
In summary, the organ donation and utilization landscape
in the United States has undergone dramatic changes in
the past years. Attention to transplant center performance
through the TGMC, organ allocation via a web-based sys-
tem and improved preservation techniques has led us as
a community to perform more transplants over the time
period of this report. However, we have reached a plateau
in conversion rates, organs transplanted per donor, and
organs from DCD. Due, in part, to the Collaborative and
mutual accountability between OPOs, transplant centers,
and donor hospitals, we have moved from a national pro-
fessionally regulated infrastructure to a national system
managed for increasing performance and continuous qual-
ity improvement. New challenges that we need to examine
are uniform donor management goals across critical care
units, utilization of all splitable livers for our pediatric pa-
tients, new allocation policies for kidney transplantation,
and wider sharing of living donor kidneys. Despite our re-
cent successes, we still have more to accomplish if we are
to serve every donor family and end deaths on the waiting
list for our patients.
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